Please login to the form below

Not currently logged in
Email:
Password:

Norgine increases ProStrakan stake

Norgine has increased its stake in Scotland-based biotech ProStrakan sparking speculation that it could be to set to make a counter bid to KHK

Dutch company Norgine has raised its stake in ProStrakan to 14 per cent, which could cause Kyowa Hakko Kirin's (KHK) £292m takeover plans to falter.

At the time of writing, shares in ProStrakan stood at 132.38p, above the 130p-a-share bid agreed with the Japanese firm earlier in the week, boosted by the prospect that Norgine could be about to make a higher bid.

In mid-November, ProStrakan refused an offer from Norgine, which purchased a 13.75 per cent stake, because it was said to have undervalued the company. The Dutch company said at the time that it had "no current intention" to mount a full-scale takeover bid.

ProStrakan has a number of products in key global markets including Sancuso (granisetron transdermal), a novel skin patch for the prevention of chemotherapy-induced nausea and vomiting, and cancer pain treatment Abstral (fentanyl).

24th February 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics